Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328770
Status:
COMPLETED
Last Update Posted:
2013-06-24
First Post:
2006-05-19
Brief Title:
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Sponsor:
University of Alberta
Organization:
University of Alberta
Study Overview
Official Title:
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Long-Term Outcomes and Side Effects
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients
Detailed Description:
A total of 70 patients with HCC mean age 546 years femalemale 1258 received a liver transplant and were included in the study Immunosuppression included de novo sirolimus low-dose calcineurin inhibitor for 6 to 12 months with short-course 3 months or no steroids
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None